Broadwood Partners, L.P. Purchases 6,730,770 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Stock

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTXGet Free Report) Director Broadwood Partners, L.P. bought 6,730,770 shares of Lineage Cell Therapeutics stock in a transaction dated Tuesday, February 6th. The shares were acquired at an average price of $1.04 per share, with a total value of $7,000,000.80. Following the completion of the purchase, the director now owns 41,666,255 shares in the company, valued at approximately $43,332,905.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX opened at $1.08 on Friday. The firm has a market cap of $188.99 million, a PE ratio of -8.31 and a beta of 1.23. Lineage Cell Therapeutics, Inc. has a one year low of $0.84 and a one year high of $1.57.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTXGet Free Report) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). The company had revenue of $1.25 million for the quarter, compared to analyst estimates of $3.30 million. Lineage Cell Therapeutics had a negative return on equity of 33.08% and a negative net margin of 262.94%. Sell-side analysts anticipate that Lineage Cell Therapeutics, Inc. will post -0.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, February 5th.

Get Our Latest Analysis on LCTX

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. BlackRock Inc. grew its holdings in Lineage Cell Therapeutics by 142.9% during the second quarter. BlackRock Inc. now owns 9,012,064 shares of the company’s stock worth $12,707,000 after acquiring an additional 5,302,486 shares during the period. Vanguard Group Inc. grew its holdings in Lineage Cell Therapeutics by 16.1% during the third quarter. Vanguard Group Inc. now owns 8,312,332 shares of the company’s stock worth $9,809,000 after acquiring an additional 1,150,633 shares during the period. Defender Capital LLC. grew its holdings in Lineage Cell Therapeutics by 1.5% during the third quarter. Defender Capital LLC. now owns 5,184,510 shares of the company’s stock worth $6,118,000 after acquiring an additional 74,800 shares during the period. Geode Capital Management LLC grew its holdings in Lineage Cell Therapeutics by 88.8% during the second quarter. Geode Capital Management LLC now owns 2,420,808 shares of the company’s stock worth $3,413,000 after acquiring an additional 1,138,808 shares during the period. Finally, State Street Corp grew its holdings in Lineage Cell Therapeutics by 1.5% during the first quarter. State Street Corp now owns 2,105,107 shares of the company’s stock worth $3,242,000 after acquiring an additional 30,873 shares during the period. 43.42% of the stock is owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

(Get Free Report)

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

See Also

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.